Literature DB >> 21219881

Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia.

Tomoyuki Tsumuraya1, Chie Ishikawa, Yoshiaki Machijima, Sawako Nakachi, Masachika Senba, Junichi Tanaka, Naoki Mori.   

Abstract

We evaluated the anti-adult T-cell leukemia (ATL) effects of hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris. Hippuristanol inhibited proliferation of HTLV-1-infected T-cell lines and ATL cells, but not normal peripheral blood mononuclear cells. It induced cell cycle arrest during G₁ phase by reducing the expression of cyclin D1, cyclin D2, CDK4 and CDK6, and induced apoptosis by reducing the expression of Bcl-x(L), c-IAP2, XIAP and c-FLIP. The induced apoptosis was associated with activation of caspase-3, -8 and -9. Hippuristanol also suppressed IkappaBalpha phosphorylation and depleted IKKalpha, IKKgamma, JunB and JunD, resulting in inactivation of NF-kappaB and AP-1. It also suppressed carbonic anhydrase type II expression. In addition to its in vitro effects, hippuristanol suppressed tumor growth in mice with severe combined immunodeficiency harboring tumors induced by inoculation of HTLV-1-infected T cells. These preclinical data suggest that hippuristanol could be a potentially useful therapeutic agent for patients with ATL.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219881     DOI: 10.1016/j.bcp.2010.12.025

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  31 in total

1.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 2.  Stress granules, P-bodies and cancer.

Authors:  Paul Anderson; Nancy Kedersha; Pavel Ivanov
Journal:  Biochim Biophys Acta       Date:  2014-12-05

Review 3.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

4.  Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.

Authors:  Cailin E Joyce; Adrienne G Yanez; Akihiro Mori; Akinori Yoda; Johanna S Carroll; Carl D Novina
Journal:  Cancer Res       Date:  2016-11-22       Impact factor: 12.701

Review 5.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 6.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

Authors:  Jerry Pelletier; Jeremy Graff; Davide Ruggero; Nahum Sonenberg
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

Review 7.  Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A.

Authors:  Regina Cencic; Jerry Pelletier
Journal:  Translation (Austin)       Date:  2016-01-04

Review 8.  Targeting RNA helicases in cancer: The translation trap.

Authors:  Marise R Heerma van Voss; Paul J van Diest; Venu Raman
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-09-28       Impact factor: 10.680

Review 9.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

10.  Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis.

Authors:  Chen-Ju Lin; Zeina Nasr; Prem K Premsrirut; John A Porco; Yoshitaka Hippo; Scott W Lowe; Jerry Pelletier
Journal:  Cell Rep       Date:  2012-04-19       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.